Physician profile
Alec David Otteman
NPI 1619138849
$456.82
in general payments reported to CMS, 2019-2025
12 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.12 · 2020: $17.79 · 2022: $120 · 2023: $121 · 2024: $38.54 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $120.02 | 2022 | |
| Nxstage Medical, INC. | $93.47 | 2023 | Liberty Select Cycler, Nxstage System One |
| Ardelyx, INC. | $52.12 | 2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.12 | 2019 | |
| Novo Nordisk INC | $27.31 | 2024-2025 | Ozempic, Wegovy |
| Calliditas Therapeutics US INC. | $25.57 | 2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $25.36 | 2024 | Jynarque |
| Fresenius USA Marketing, INC. | $17.79 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.70 | 2025 | |
| Travere Therapeutics, INC. | $16.45 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $14.49 | 2023 | Farxiga |
| Aurinia Pharma U.S., INC. | $13.42 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alec Otteman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.